Wire · regulatory
Dr Reddy's Secures US FDA Approval for Rituximab Biosimilar, Expands Biologics Portfolio
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 August 2026 · Fusion42 review
Dr Reddy's Laboratories has received US FDA approval for its rituximab biosimilar, expanding its biologics portfolio and presence in the US pharmaceutical market. Fresenius Kabi will exclusively commercialise the biosimilar in the United States following a successful FDA inspection of Dr Reddy's Hyderabad manufacturing facility.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 1 Aug 2026 and 14 Aug 2026.
◆ ◆ The Wire takeaway
Your biologics company has a clear path to enter the US market with complex biosimilars now cleared by FDA. You need to finalise partnerships for commercialisation to capitalise fast on this regulatory opening.
◆ Coverage
5 sources · first reported 1 Aug 2026 · latest 14 Aug 2026
◆ Related on Wire
◆ Topics